Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the egrifta (tesamorelin acetate) market grown in recent years?

In recent times, the egrifta (tesamorelin acetate) market has expanded by XX (HCAGR). The market size is projected to rise from $XX million in 2024 to $XX million in 2025, signifying a compound annual growth rate (CAGR) of XX%. This expansion during the historic period can be credited to the surge in understanding of HIV-related complications, escalating demand for medication therapy, increased application of antiretroviral therapy, heightened emphasis on quality of life, progress in medical research, and rising awareness.

How is the egrifta (tesamorelin acetate) market size expected to evolve during the forecast period?

Predictions suggest that the egrifta (tesamorelin acetate) market size will exhibit a CAGR of XX%, expanding to a valuation of $XX million by 2029. Several factors are contributing to this predicted growth over the forecasted period, including the increasing incidences of chronic diseases, the expansion in the number of hospitals, escalating demand for advanced health monitoring equipment, a rise in metabolic disorders’ occurrence and an increase in disease treatment awareness. The approaching period is also expected to see significant trends such as the growing use of precision treatments, integration with all-encompassing healthcare plans, the evolution of personalized medicine, the advancement in patient assistance programs, and an uptick in research endeavors.

Get your egrifta (tesamorelin acetate) market report here!

https://www.thebusinessresearchcompany.com/report/egrifta-tesamorelin-acetate-global-market-report

Which key drivers are propelling the egrifta (tesamorelin acetate) market’s growth?

The escalation of human immunodeficiency virus (HIV) incidences is providing substantial impetus to the growth of the egrifta (tesamorelin acetate) market in the coming years. The term HIV incidences denotes scenarios where people have contracted the HIV virus, causing their immune systems to deteriorate over time. Among the reasons for the spread of HIV are inadequate awareness and education regarding preventive methods, encompassing the usage of condoms and frequent screenings, notably within high-risk communities. Egrifta induces the secretion of the growth hormone, lowering excess internal fat and enhancing body composition. This, in turn, augments the overall health and quality of life in persons with HIV. For instance, the Minnesota Department of Health, a health agency based in the US, reported 324 fresh HIV cases in 2023, reflecting a 24% increase from 2022 in May 2024. Therefore, the heightened prevalence of human immunodeficiency virus (HIV) incidences is fueling the growth of the egrifta (tesamorelin acetate) market.

What are the market segments in the egrifta (tesamorelin acetate) industry?

The egrifta (tesamorelin acetate) market covered in this report is segmented –

1) By Clinical Indication: Human Immunodeficiency Virus (HIV)-Associated Lipodystrophy, Growth Hormone Deficiency, Abdominal Obesity, Metabolic Syndrome

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

3) By End-Users: Hospitals, Specialized Clinics, Home Care

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20043&type=smp

Which leading companies are shaping the growth of the egrifta (tesamorelin acetate) market?

Major companies operating in the egrifta (tesamorelin acetate) market include Theratechnologies Inc.

What key trends are currently impacting the egrifta (tesamorelin acetate) market’s development?

The primary trend in the egrifta (tesamorelin acetate) market is the concentrated effort on the development of sophisticated synthetic peptide drugs to augment efficiency in HIV-related lipodystrophy treatments. Synthetic peptide medication is engineered substances aimed at delivering a targeted therapeutic impact by simulating or boosting the functions of naturally produced peptides. Take, for example, Theratechnologies Inc., a Canadian biopharmaceutical firm announced the recommencement of EGRIFTA SV’s production in December 2024, after a deliberate shutdown of its contract manufacturer’s factory in response to FDA inspection findings. A newly produced batch has concluded quality control, awaiting the US Food and Drug Administration’s approval for a supplementary prior approval, while an extra two batches are still within their production phase. The firm is handling inventory in preparation for patient needs by mid-January 2025 and collaborating with the FDA in planning to avert potential scarcity in 2025. EGRIFTA SV is currently only available in the United States.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20043

Which geographic areas are influencing the growth of the egrifta (tesamorelin acetate) market?

North America was the largest region in the egrifta (tesamorelin acetate) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egrifta (tesamorelin acetate) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Hormone Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Parathyroid Hormone Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

Follicle Stimulating Hormone Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/follicle-stimulating-hormone-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: